ReviewEvolution, medicine, and public health2016
Beyond killing: Can we find new ways to manage infection?
Review in Evolution, medicine, and public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 81 citations in OpenAlex.
- Phenotypic high-content screening identifies plant-derived extracts targeting microbial growth, biofilms and swarming activity.Frontiers in microbiology · 2026Article
- Anti-infective compounds forSustainable microbiology · 2026Review
- Targeting virulence to disarm the pathogen: Enzyme-activated-substrate inhibition of Anthrax edema factor.Bioorganic & medicinal chemistry letters · 2025Article
- Headway in Synthetic Chemistry: A Gateway for Antimicrobial Trojan Horse Strategy for Drug Repurposing Against Multi-Drug ResistantIndian journal of microbiology · 2025Review
- Bacillus velezensis iturins inhibit the hemolytic activity of Staphylococcus aureus.Scientific reports · 2024Article
- Unveiling the hidden language of bacteria: anti-quorum sensing strategies for gram-negative bacteria infection control.Archives of microbiology · 2024Review
- Targeting multidrug resistantChemical science · 2023Article
- Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- An assembled bacterial community associated withFrontiers in microbiology · 2023Article
- The cost of host genetic resistance on body condition: Evidence from divergently selected sheep.Evolutionary applications · 2022Article
- Mechanisms of damage prevention, signalling and repair impact disease tolerance.Proceedings. Biological sciences · 2022Article
- Review
- Review: Livestock disease resilience: from individual to herd level.Animal : an international journal of animal bioscience · 2021Review
- Antivirulence DsbA inhibitors attenuateFASEB bioAdvances · 2021Article
- Xylopic acid-amodiaquine and xylopic acid-artesunate combinations are effective in managing malaria in Plasmodium berghei-infected mice.Malaria journal · 2021Article
- Cysteamine Inhibits Glycine Utilisation and Disrupts Virulence inFrontiers in cellular and infection microbiology · 2021Article
- Putative determinants of virulence inVirulence · 2020Article
- Controlling foodborne pathogens with natural antimicrobials by biological control and antivirulence strategies.Heliyon · 2020Review
- Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa.PLoS biology · 2020Article
- Proliferation and benevolence-A framework for dissecting the mechanisms of microbial virulence and health promotion.Evolutionary applications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
Abstract
The antibiotic pipeline is running dry and infectious disease remains a major threat to public health. An efficient strategy to stay ahead of rapidly adapting pathogens should include approaches that replace, complement or enhance the effect of both current and novel antimicrobial compounds. In recent years, a number of innovative approaches to manage disease without the aid of traditional antibiotics and without eliminating the pathogens directly have emerged. These include disabling pathogen virulence-factors, increasing host tissue damage control or altering the microbiota to provide colonization resistance, immune resistance or disease tolerance against pathogens. We discuss the therapeutic potential of these approaches and examine their possible consequences for pathogen evolution. To guarantee a longer half-life of these alternatives to directly killing pathogens, and to gain a full understanding of their population-level consequences, we encourage future work to incorporate evolutionary perspectives into the development of these treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.